In a BSE filing, Cipla said "its subsidiary, InvaGen Pharmaceuticals Inc. has received final approval for its abbreviated new drug application (ANDA) for Sevelamer Carbonate Tablets, 800 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback